The GLP-1 Blueprint for Patients and Practitioners

Welcome to Cell to Systems. I'm Jock Putney, and today we’re talking about the current landscape of the GLP-1 world. As we’ve seen in major media and Super Bowl commercials, GLP-1s are everywhere. The topic of today’s show is how to run a GLP-1 program safely and successfully, whether you are a patient looking to use them the right way or a clinician looking to provide them in a proper program.

Dr. Leonard Pastrana notes that there is a lot happening in the industry, with new guidance, regulatory updates, and studies coming out daily. The most successful practices prioritize three things. First, they don't just call it a "GLP-1 program"; they treat it as a longevity program where GLP-1s are simply one tool. These clinics thrive by having a different conversation that considers the patient as a whole, including family history, genetic predispositions, and cardiometabolic risk.

Second, thriving practices focus heavily on education and communication. A practice cannot scale if knowledge is trapped; therefore, educating the staff and other practitioners is vital because the staff often handles the bulk of patient communication. Finally, successful programs must evolve over time. A major red flag is a program where a patient stays on the exact same dose for six months without change. As biochemistry and biomarkers shift, the treatment must pivot.

Green and Red Flags for Patients

For patients, the green lights to look for are very similar to what makes a practice successful. A significant red flag is a clinic that leads with price or simply markets the drug itself rather than an assessment of your risks and priorities. You want a provider who personalizes treatment and measures more than just the number on the scale or BMI. If they aren't looking at body composition, metabolism, and other biomarkers, they are missing the full picture.

Furthermore, your plan should change over time. In longevity medicine, providers look at both healthspan—the current quality of your life—and lifespan—what will impact you down the road. As you eliminate certain risks, the medical plan should adjust accordingly.

Moving Beyond Simple Weight Loss

Dr. Suzanne Ferree discusses the importance of setting guardrails for patients who want to lose weight as fast as possible. In her practice, they have moved away from traditional "weight loss programs" because they aren't consistent with the goal of comprehensive longevity. Success depends on a patient’s stress, lifestyle choices, and environmental factors. If a patient refuses to change anything else and only wants a GLP-1, they aren't the right fit for this type of clinical environment.

Comprehensive care involves dietitians, body impedance analysis (BIA), and extensive labs to check levels like reverse T3, albumin, and lymphocyte counts. The goal is to ensure the patient is overall healthy. A proper protocol also includes supplements like protein, creatine, amino acids, and minerals to maintain hydration and muscle mass. Without these, patients may suffer from "sarcopenic" weight loss—losing muscle instead of the visceral fat that actually drives disease.

Pharmacy Safety and the Risk of Research Peptides

Dr. Franck Kacou, a pharmacist, highlights the legal and safety issues currently facing the industry. Big pharma companies like Novo Nordisk are becoming more aggressive with lawsuits against companies for copycat products and intellectual property issues. For patients, the "elephant in the room" is research peptides. Many patients are tempted to buy these online or via social media, but they are highly discouraged.

Research peptides, including those not yet FDA-approved like retatrutide, lack consistent safety testing. While a company might provide a Certificate of Analysis (COA), this is often just a "snapshot in time" from a single test. In contrast, a licensed 503A or 503B compounding pharmacy must test every single batch before it is released to the public. Patients should focus on finding a provider who can guide them through the journey safely, potentially leveraging brand-name drugs if the patient prefers, as prices for brand names are becoming more competitive.

Legal Compounding and the Patient Experience

Compounding GLP-1s is not illegal; the issue lies in "mass compounding" or creating thousands of batches in anticipation of prescriptions without a specific patient need. To stay within legal guardrails, physicians must document the specific reason why a patient requires a compounded version—such as the need for a customized dose. This allows longevity physicians to build a sustainable business focused on the patient's journey rather than just marketing a drug.

Krisit, a clinic owner, emphasizes that the patient experience starts the moment they walk in. She only partners with patients who have a genuine desire to live healthily. Adding in-house health coaches and nutritionists has been a game-changer for patients whose weight loss has stalled. These coaches walk through the patient's daily life to identify barriers like stress or poor hydration. Awareness must come before change, and supporting the patient through hormone optimization and education on cellular hydration is essential for improving body composition.

Precise Treatment and Data-Driven Insights

Craig explains that at his practice, Remedy, GLP-1 therapy is not the centerpiece. Transformation happens through personalization based on comprehensive labs—chemistry, inflammatory markers, lipids, and hormones. By identifying root drivers of metabolic dysfunction and using tools like the InBody scale, they can monitor skeletal muscle mass and visceral organ fat. Visceral fat is particularly dangerous as it drives diabetes, dementia, and hormonal dysfunction.

They also use metabolic breath analysis (Pnoe) to measure VO2 max, which is a top metric for longevity. This data helps providers understand a patient's mitochondrial function and metabolic flexibility—their ability to switch between burning carbs and fat. Following up every few weeks is necessary to check for side effects and ensure the patient is drinking enough water (at least half their body weight in ounces).

Non-Negotiables for Success

The team concludes with their "non-negotiables" for success. For patients, exercise is the greatest amplifier of a GLP-1 program, while stress and poor sleep are the greatest drivers of failure. For physicians, the non-negotiable is building value outside of the drug itself; if the practice relies solely on the prescription for its financial health, it won't last.

Practitioners must also provide a "playbook"—a written plan for dosing, escalation, and muscle protection. Finally, the most significant failure point in the industry is the "refill without follow-up." Simply calling in prescriptions every few months without reassessing labs or biomarkers puts the patient at risk for unnecessary dose increases and rapid weight regain once the medication is stopped. True longevity medicine requires a high-touch, personalized relationship between the provider, the pharmacy, and the patient.